Print Preview Area

Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases
Multiple Sclerosis Journal, 08/02/2012

Hakiki B et al. – The findings suggest that clinical and magnetic resonance (MR) outcomes after fingolimod suspension can vary among patients. Systematic collection of clinical, laboratory and imaging data is highly advisable to identify subjects who are at higher risk of rebound and to define effective management strategies in these subjects.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Physician Assistant Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases Multiple Sclerosis Journal, 08/02/2012

Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases
Multiple Sclerosis Journal, 08/02/2012